Delcath Systems
This article was originally published in The Gray Sheet
Executive Summary
National Cancer Institute Phase II study of the firm's catheter-based perfusion technology to deliver the chemotherapy drug melphalan will begin "shortly" to treat primary hepatic tumors and metastatic liver cancer originating from adenocarcinoma, neuro-endocrine or melanoma cancers. Data from 18 patients in the Phase I NCI study showed that more aggressive melphalan treatment is possible using the local delivery technique. Anti-tumor activity was achieved in 75%, or six of eight subjects with inoperable metastatic liver cancers that began as ocular melanoma, Delcath says...